ERK1/2-targeted Cancer therapies: Recent advances, potential drug resistance, and applicability analysis of emerging technologies.

ulixertinib (BVD-523) - BioMed Valley Discoveries

http://www.ncbi.nlm.nih.gov/pubmed/41865566

Hu He; Jiawei Zhao; Jishun Quan; Qin Yin; Tianyu Niu; Xinyue Mao; Zhuo Zhang

Mar 25, 2026